Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  The Lancet Respiratory Medicine

• Publication date

  2016-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S2213-2600(16)30227-2PMID 27574788
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacological Characterization of AZD5069, a Slowly Reversible CXC Chemokine Receptor 2 Antagonist

  2015cited by this paper
• The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions.

  2015cited by this paper
• A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis

  2015cited by this paper
• CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.

  2015cited by this paper
• Therapeutic implications of ‘neutrophilic asthma’

  2015cited by this paper
• The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.

  2015cited by this paper
• Full blood count parameters for the detection of asthma inflammatory phenotypes

  2014cited by this paper
• Stability of phenotypes defined by physiological variables and biomarkers in adults with asthma

  2014cited by this paper
• EGF-Induced Bronchial Epithelial Cells Drive Neutrophil Chemotactic and Anti-Apoptotic Activity in Asthma

  2013cited by this paper
• Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis.

  2013cited by this paper
• Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo‐controlled clinical trial

  2012cited by this paper
• Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy

  2011cited by this paper
• Regulation of neutrophil trafficking from the bone marrow

  2011cited by this paper
• Neutrophils in chronic inflammatory airway diseases: can we target them and how?

  2010cited by this paper
• Prosurvival activity for airway neutrophils in severe asthma

  2010cited by this paper
• CXCR2 antagonists for the treatment of pulmonary disease.

  2009cited by this paper
• A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma.

  2009cited by this paper
• Targeting TNF-α: A novel therapeutic approach for asthma

  2008cited by this paper
• Targeting TNF-alpha: a novel therapeutic approach for asthma.

  2008cited by this paper
• A Novel, Orally Active CXCR1/2 Receptor Antagonist, Sch527123, Inhibits Neutrophil Recruitment, Mucus Production, and Goblet Cell Hyperplasia in Animal Models of Pulmonary Inflammation

  2007cited by this paper
• Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma

  2007cited by this paper
• Neutrophils in asthma

  2007cited by this paper
• Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities.

  2006cited by this paper
• Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE

  2005cited by this paper
• Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR

  2004cited by this paper
• Effect of HFA-flunisolide on peripheral lung inflammation in asthma.

  2003cited by this paper
• Generalized Linear Models

  2002cited by this paper
• Pathophysiology of severe asthma.

  2000cited by this paper
• Non-eosinophilic corticosteroid unresponsive asthma.

  1999cited by this paper
• Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation.

  1995cited by this paper
• Exacerbations of asthma without sputum eosinophilia.

  1995cited by this paper
• Neutrophils in Asthma a

  1991cited by this paper
• Generalized Linear Models, 2nd Edn.

  1990cited by this paper

• Precision Medicine for Asthma: Tailored to its Severity and Endotype/Phenotype

  2026cites this paper
• CXCR2 antagonism as a promising therapeutic approach for pulmonary fibrosis therapy.

  2026cites this paper
• When Neutrophils Go Rogue: Dysregulated Inflammation in Airway Diseases and Implications for Therapy.

  2026cites this paper
• Neutrophil Plasticity in Airway Disease: Balancing Damage and Repair

  2025cites this paper
• Allergic Contact Dermatitis: Immunopathology and Potential Therapeutic Strategies

  2025cites this paper
• Trajectory‐Based Clustering to Identify Asthma Subgroups Responsive to the Selective CXCR2 Antagonist, AZD5069

  2025cites this paper
• Analysis of airway inflammation demonstrates a mechanism for T2-biologic failure in asthma.

  2025cites this paper
• Development of a protocol complexity tool: a framework designed to stimulate discussion and simplify study design

  2025cites this paper
• Chemokine receptors in GtoPdb v.2025.3

  2025cites this paper
• The Interleukin-8-CXCR1/2 Axis as a Therapeutic Target in Peritoneal Carcinomatosis

  2025cites this paper
• Role of the tumor microenvironment in chemotherapy resistance in ovarian cancer and targeted therapy

  2025cites this paper
• Precision Medicine in Asthma: The Role of Biomarkers

  2025cites this paper
• Autocrine CXCL1-CXCR2 Signaling Mediates Leptomeningeal Resistance to Radiation Therapy

  2025cites this paper
• Breaking the bottleneck of asthma treatment: the future of omni-targeted therapy.

  2025cites this paper
• Discovery of PF-07054894, a Potent Squaramide-Based CCR6 Antagonist Displaying High CXCR2 Selectivity.

  2025cites this paper
• The CXCL1-CXCR2 Axis as a Component of Therapy Resistance, a Source of Side Effects in Cancer Treatment, and a Therapeutic Target

  2025cites this paper
• Chemokine receptors in GtoPdb v.2025.1

  2025cites this paper
• Targeting Neutrophil-Mediated Inflammation: Identification of Pyrazolidinone Carboxamide Derivatives as Potent Selective Inhibitors of Formyl Peptide Receptor 1 (FPR1)-Activated Neutrophils.

  2025cites this paper
• [Design and inflammation-targeting efficiency assessment of an engineered liposome-based nanomedicine delivery system targeting E-selectin].

  2025cites this paper
• Neutrophilic Asthma—From Mechanisms to New Perspectives of Therapy

  2025cites this paper
• Pulmonary Emphysema: Current Understanding of Disease Pathogenesis and Therapeutic Approaches

  2025cites this paper
• Neutrophil heterogeneity and plasticity: unveiling the multifaceted roles in health and disease

  2025cites this paper
• The dilemma of the asthmatic patient: fight with the help of drugs or escape to a healthier environment?

  2025cites this paper
• Targeting CXCR2 signaling in inflammatory lung diseases: neutrophil-driven inflammation and emerging therapies

  2025cites this paper
• Overcoming immunotherapy resistance in hepatocellular carcinoma by targeting myeloid IL-8/CXCR2 signaling

  2025cites this paper
• The immunology of asthma and chronic rhinosinusitis

  2025cites this paper
• Established and Emerging Asthma Biomarkers with a Focus on Biologic Trials: A Narrative Review

  2025cites this paper
• Immunotherapy for asthma

  2025cites this paper
• Adverse effects of CXCR2 deficiency in mice reared under non-gnotobiotic conditions

  2024cites this paper
• The role and mechanism of extracellular traps in chronic rhinosinusitis.

  2024cites this paper
• Update on Inflammatory Biomarkers for Defining Asthma Phenotype

  2024cites this paper
• A microphysiological system reveals neutrophil contact-dependent attenuation of pancreatic tumor progression by CXCR2 inhibition-based immunotherapy

  2024cites this paper
• Crosstalk of pyroptosis and cytokine in the tumor microenvironment: from mechanisms to clinical implication

  2024cites this paper
• Neutrophil and neutrophil extracellular trap involvement in neutrophilic asthma: A review

  2024cites this paper
• CXCR2 perturbation promotes Staphylococcus aureus implant-associated infection

  2024cites this paper
• Immune Cell-Mediated Autoimmune Responses in Severe Asthma

  2024cites this paper
• Advances in non-type 2 severe asthma: from molecular insights to novel treatment strategies

  2024cites this paper
• Neutrophil extracellular traps and their implications in airway inflammatory diseases

  2024cites this paper
• New targets for type 2-low asthma

  2024cites this paper
• Development and Initial Characterization of the First 18F-CXCR2-Targeting Radiotracer for PET Imaging of Neutrophils.

  2024cites this paper
• Preventing progression of preschool wheezing to asthma: Opportunities for intervention

  2024cites this paper
• Selective anti-CXCR2 receptor blockade by AZD5069 inhibits CXCL8-mediated pro-tumorigenic activity in human thyroid cancer cells in vitro

  2024cites this paper
• Spatiotemporal control of neutrophil fate to tune inflammation and repair for myocardial infarction therapy

  2024cites this paper
• Beyond binary: bridging neutrophil diversity to new therapeutic approaches in NSCLC.

  2024cites this paper
• Neutrophil Extracellular Traps and Respiratory Disease

  2024cites this paper
• Asthma Pathogenesis: Phenotypes, Therapies and Gaps. Summary of the Aspen Lung Conference 2023.

  2024cites this paper
• Biomarkers of type 2 and non-type 2 inflammation in asthma exacerbations

  2024cites this paper
• Understanding CXCR2 antagonism with a dynamic allosteric ternary complex model.

  2024cites this paper
• Immunological factors, important players in the development of asthma

  2024cites this paper
• Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates

  2023cites this paper
• Clinical Trial Design Innovations for Precision Medicine in Asthma.

  2023cites this paper
• Blood transcriptomic signature in type-2 biomarker low severe asthma and asthma control.

  2023cites this paper
• Obesity alters inflammatory response in the pathology of asthma (Review).

  2023cites this paper
• A Comparative Inflammation‐on‐a‐Chip with a Complete 3D Interface: Pharmacological Applications in COPD‐Induced Neutrophil Migration

  2023cites this paper
• Type-2-low severe asthma endotypes for new treatments: the new asthma frontier.

  2023cites this paper
• A Novel C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) Antagonist (PF-07054894) Distinguishes between Homologous Chemokine Receptors, Increases Basal Circulating CCR6+ T Cells, and Ameliorates Interleukin-23-Induced Skin Inflammation

  2023cites this paper
• New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis

  2023cites this paper
• T2-Low Asthma: A Discussed but Still Orphan Disease

  2023cites this paper
• Development of tolerance to chemokine receptor antagonists: current paradigms and the need for further investigation

  2023cites this paper
• Therapeutic inhibition of CXCR1/2: where do we stand?

  2023cites this paper
• Neutrophil Extracellular Traps in Airway Diseases: Pathological Roles and Therapeutic Implications

  2023cites this paper
• Uncoupling hepatic insulin resistance – hepatic inflammation to improve insulin sensitivity and to prevent impaired metabolism-associated fatty liver disease in type 2 diabetes

  2023cites this paper
• ST2-Mediated Neutrophilic Airway Inflammation: A Therapeutic Target for Patients With Uncontrolled Asthma

  2023cites this paper
• The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention

  2023cites this paper
• Neutrophils in Health and Disease: From Receptor Sensing to Inflammasome Activation

  2023cites this paper
• Design of an effective small expression tag to enhance GPCR production in E. coli‐based cell‐free and whole cell expression systems

  2023cites this paper
• Enhancing the efficacy of vaccinia-based oncolytic virotherapy by inhibiting CXCR2-mediated MDSC trafficking.

  2023cites this paper
• Sex-Based Differences in Bronchial Asthma: What Are the Mechanisms behind Them?

  2023cites this paper
• CXCR2 chemokine receptor - a master regulator in cancer and physiology.

  2023cites this paper
• Dual inhibition of airway inflammation and fibrosis by common beta cytokine receptor blockade.

  2023cites this paper
• CXCL6: A potential therapeutic target for inflammation and cancer

  2023cites this paper
• A Decade of Pathogenesis Advances in Non-Type 2 Inflammatory Endotypes in Chronic Rhinosinusitis: 2012–2022

  2023cites this paper
• Cytokine-targeted therapies for asthma and COPD

  2023cites this paper
• Promising treatment biomarkers in asthma

  2023cites this paper
• Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils

  2023cites this paper
• Current unmet needs and potential solutions to uncontrolled asthma

  2022cites this paper
• RETRACTED ARTICLE: Pharmacological perturbation of CXCL1 signaling alleviates neuropathogenesis in a model of HEVA71 infection

  2022cites this paper
• The onset, development and pathogenesis of severe neutrophilic asthma

  2022cites this paper
• Neutrophil extracellular traps in chronic lung disease: implications for pathogenesis and therapy

  2022cites this paper
• Increase in Blood Eosinophil Count Over Time and Sputum IL8 are Associated with FEV1 Decline in Asthma

  2022cites this paper
• Asthma Management in Adults.

  2022cites this paper
• Neutrophil interactions with T cells, platelets, endothelial cells, and of course tumor cells

  2022cites this paper
• CXCR2 Mediates Distinct Neutrophil Behavior in Brain Metastatic Breast Tumor

  2022cites this paper
• Neutrophil-Lymphocyte Ratio Predicting Case Severity in SARS-CoV-2 Infection: A Review

  2022cites this paper
• Improvement in insulin sensitivity and prevention of high fat diet-induced liver pathology using a CXCR2 antagonist

  2022cites this paper
• Myeloid-derived suppressor cells in cancer

  2022cites this paper
• Targeting CXCR1 and CXCR2 receptors in cardiovascular diseases.

  2022cites this paper
• Novel Therapeutic Strategies in Asthma-Chronic Obstructive Pulmonary Disease Overlap.

  2022cites this paper
• Multifaceted Roles of Chemokine C-X-C Motif Ligand 7 in Inflammatory Diseases and Cancer

  2022cites this paper
• Thérapeutique immunologique ciblée dans l’asthme

  2022cites this paper
• Mechanisms regulating neutrophil responses in immunity, allergy, and autoimmunity

  2022cites this paper
• Investigational approaches for unmet need in severe asthma

  2022cites this paper
• Neutrophils and Asthma

  2022cites this paper
• Paucigranulocytic Asthma: Potential Pathogenetic Mechanisms, Clinical Features and Therapeutic Management

  2022cites this paper
• Novel potential treatable traits in asthma: Where is the research taking us?

  2022cites this paper
• Surgery-Mediated Tumor-Promoting Effects on the Immune Microenvironment.

  2022cites this paper
• Влияние севофлурана на активацию нейтрофилов человека в моделях ex vivo

  2022cites this paper
• An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma

  2022cites this paper
• MAPK activated kinase 2 inhibition shifts the chemokine signature in arthritis synovial fluid mononuclear cells from CXCR3 to CXCR2.

  2022cites this paper
• Longitudinal Impact of Sputum Inflammatory Phenotypes on Small Airway Dysfunction and Disease Outcomes in Asthma.

  2022cites this paper